EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, WINT: Windtree Therapeutics Inc

28 Nov 2025
LAST:

0.0433

CHANGE:
 0.01		OPEN:
0.0420		HIGH:
0.0533		ASK:
0.0000		VOLUME:
5.7K
CHG(%):
13.23		PREV:
0.0499		LOW:
0.0420		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Nov 250.04200.05330.04200.04335.7K
26 Nov 250.05800.05800.04100.0499501.1K
25 Nov 250.04860.05800.04860.0580140.2K
24 Nov 250.05370.06190.04850.0570242.1K
21 Nov 250.05030.06060.05020.0600167.9K
20 Nov 250.05000.05700.04750.0504128.0K
19 Nov 250.05900.06470.04320.0490491.4K
18 Nov 250.05810.06440.05810.0590113.7K
17 Nov 250.06200.07000.05800.06001.04M
14 Nov 250.06230.07000.06210.0650170.4K

PROFILE

Name:Windtree Therapeutics Inc
About:Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Sector:Healthcare
Industry:Biotechnology
Address:2600 Kelly Road, Warrington, PA, United States, 18976-3622
Website:https://windtreetx.com
CUSIP:97382D303
CIK:0000946486
ISIN:US97382D3035
FIGI:BBG000JMNPX3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.00 
Forward P/E:0.37 
Price to Sales:660.53 
Price to Book:0.61 
Shares:29.33M 
Market Cap:1.27M 

TECHNICAL INDICATORS

MA5:0.0523.8%
MA10:0.0627.5%
MA20:0.0754.3%
MA50:0.09107.9%
RSI14:31.59 
WPR14:-100.00 
MTM14:-0.03
ROC14:-0.44 
ATR:0.01 
Week High:0.0643.0%
Week Low:0.045.6%
Month High:0.12177.1%
Month Low:0.04
Volatility:52.37